Seven major European drugmakers joined with other pharma companies, academics and other collaborators in a €196 million ($262.6 million) project to share and screen hundreds of thousands of compounds. Report
Europe's pharma community is revving up a drug-discovery engine. A new effort involving 30 partners--including Bayer, Johnson & Johnson's Janssen and 5 other large pharmas--has launched to spark discovery of new treatments, using a crowd-sourcing and open innovation approach.
What would top Xarelto for Bayer and Johnson & Johnson? Xarelto with an easy antidote.
France's drug regulators last year faced scathing criticism for dragging their feet when it came to the dangers of off-label use of diabetes drug Mediator. Now faced with consumer fears over deaths tied to off-label use of Bayer acne drug, Diane-35, they are acting with dispatch.
With a new chairman selected to take the helm of Novartis, lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.
Harris Interactive has been digging into physicians' response to drug brands, therapeutic area by therapeutic area, racking up more evidence for an emotional variable in the doctor-drug trust equation.
The U.K.'s cost-effectiveness watchdogs must really like Eliquis. The new blood thinner from Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) won a thumbs-up for stroke prevention.
For the first time in 12 years, the U.S. has a new IUD approved for commercial use, and Bayer is bringing it to market in early February.
Bayer has another foe in its battle to defend the contraceptive pill Yasmin. Switzerland's biggest insurer, CSS, is backing a woman's claims against the German company, joining in her lawsuit that alleges Yasmin triggered her disabling pulmonary embolism.
Novartis is one step closer to marketing Lucentis in a new group of patients. The National Institute for Health and Clinical Excellence officially changed its mind on the Swiss drugmaker's eye treatment, recommending the pricey injection for use in diabetics.